ToleroGenics S.à.r.l. is focused on pioneering innovative therapies for allergy and autoimmune diseases through its advanced technologies aimed at inducing immune tolerance. Central to their approach is the use of patent-protected technologies, including the thermosensitive ImmuneGel, which allows for sustained local release of therapeutic agents via subcutaneous injection. This hydrogel not only serves as a drug depot but also employs the PhagoAttract technology to recruit antigen-presenting cells (APCs) to enhance immune modulation. Additionally, the company utilizes peptide-loaded tolerizing PS-liposomes through its ToleroAIT technology, which promotes the generation of regulatory T cells (Tregs) that help restore a balanced immune response by suppressing harmful effector T cells.

The company’s product pipeline includes novel immunotherapies targeting specific allergies, such as those related to insect venom, house dust mites, and birch tree pollen. ToleroGenics is also exploring partnerships for the development of therapies for other allergic and autoimmune conditions. Their technologies, including the ToleroSphere and ToleroLiposphere, leverage hydrogel-embedded nanoparticles and liposomes to enhance the efficacy of immunotherapy by mimicking natural tolerance mechanisms and promoting the conversion of dendritic cells into tolerogenic forms. This comprehensive approach positions ToleroGenics as a leader in the next generation of immunotherapy solutions.

Luxembourg

Tolerogenics S.à.r.l. has developed several key technologies to overcome today’s bottlenecks in immunotherapy treatment. Tolerogenic’s has used these technologies to create a novel patent-protected approach of tolerance induction to achieve long-term cure of allergy diseases. The experienced management of Tolerogenics willprovide the strategic and regulatory support to bring the products to market.

ToleroGenics

Company Details